Skip to main content

Press Releases and Ad-hoc Announcements

17 December 2025	Letter from the CEO	PDF
24 November 2025	PR: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer	PDF
24 November 2025	AH: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer	PDF
06 November 2025	PR: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma	PDF
03 November 2025	Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar	PDF
23 October 2025	PR: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma	PDF
09 October 2025	Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025	PDF
06 October 2025	AH: Heidelberg Pharma AG Announces Updated Guidance	PDF
25 September 2025	PR: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma	PDF
25 September 2025	PR: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment	PDF
25 September 2025	AH: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment	PDF
04 September 2025	PR: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025	PDF
28 August 2025	AH: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx	PDF
10 July 2025	PR: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business	PDF
27 May 2025	PR: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma	PDF
15 May 2025	PR: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board	PDF
14 May 2025	PR: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025	PDF
24 April 2025	PR: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025	PDF
26 March 2025	PR: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025	PDF
21 March 2025	PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024	PDF
13 March 2025	PR: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty	PDF
13 March 2025	AH: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty	PDF
13 January 2025	PR: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma	PDF